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Immunotherapy Targeting Adenosine Synthase 
A Decreases Severity of Staphylococcus aureus Infection in 
Mouse Model
Bao-Zhong Zhang,1,2,4 JianPiao Cai,2 Bin Yu,1,3 Lifeng Xiong,2 Qiubin Lin,1,5 Xiao-Yan Yang,1 Chen Xu,1,5 SongYue Zheng,1 Richard Yi-Tsun Kao,2 
Konghung Sze,2 Kwok-Yung Yuen,2,3,a and Jian-Dong Huang1,4,5,a
1School of Biomedical Sciences, 2Department of Microbiology, and 3State Key Laboratory of Emerging Infectious Diseases, University of Hong Kong; and 4HKU-Shenzhen Institute 
of Research and Innovation and 5Centre for Synthetic Biology Engineering Research; Shenzhen Institutes of Advanced Technology, Guangdong, China
Staphylococcus aureus is a severe pathogen found in the community and in hospitals. Most notably, methicillin-resistant S. aureus 
(MRSA) is resistant to almost all antibiotics, which is a growing public health concern. The emergence of drug-resistant strains has 
prompted the search for alternative treatments such as immunotherapeutic approaches. Previous research showed that S. aureus 
exploit the immunomodulatory attributes of adenosine to escape host immunity. In this study, we investigated adenosine synthase 
A (AdsA), an S. aureus cell wall–anchored enzyme as possible targets for immunotherapy. Mice vaccinated with aluminum hydrox-
ide–formulated recombinant AdsA (rAdsA) induced high-titer anti-AdsA antibodies, thereby providing consistent protection in 3 
mouse infection models when challenged with 2 S. aureus strains. The importance of anti-AdsA antibody in protection was demon-
strated by passive transfer experiments. Moreover, AdsA-specific antisera promote killing S. aureus by immune cells. Altogether, our 
data demonstrate that the AdsA is a promising target for vaccines and therapeutics development to alleviate severe S. aureus diseases.
Keywords. S. aureus; adenosine synthase A; AdsA; immunotherapy.
 
Staphylococcus aureus is a common pathogen in the community 
and frequently found in hospitals [1–4]. Particularly, methicil-
lin-resistant S.  aureus (MRSA) is one of the more dangerous 
antibiotic-resistant S. aureus strains. The strains are prevalent in 
hospitals and are fast becoming a common community-acquired 
infection [5]. For this reason, research into the development of 
immunotherapeutic approaches, either active or passive, has 
seen a resurgence in recent years [6]. At least 13 secreted pro-
teins and 24 surface adhesion proteins from S. aureus have been 
implicated in the bacterial immune evasion, many of which 
have been evaluated as potential antigens [7–16]. Current and 
past S. aureus vaccines or therapeutic antibody strategies have 
mainly focused on virulence factors, capsular polysaccharide 
(CPS) and iron-regulated proteins, including ess extracellu-
lar A  (EsxA) and ess extracellular B (EsxB) [17], alpha toxin 
(nontoxic derivative of H35L) [8, 18], clumping factor A (ClfA) 
[19], fibronectin binding protein (FnBPA or FnBPB) [13], 
Panton-Valentine leukocidin (PVL) [20], and protein A  [12]. 
Iron-regulated proteins have also been investigated as another 
possible target for vaccines against S.  aureus, such as Merck 
V710, which is based on the iron-regulated surface determinant 
B (IsdB) [7, 21]. To date, most of the clinical trials for vaccines 
or passive immunization against S. aureus have ended in failure. 
Therefore, investigations of other potential antigens are very 
important to develop S. aureus vaccine.
S. aureus has a unique ability to escape a variety of innate 
immune responses, such as phagocytic killing and complement 
and antimicrobial peptides, thereby leading to survival in blood 
or other host tissues, causing persistent infections [22]. S. aureus 
deploys a range of mechanisms, such as secretion of virulent fac-
tors and toxins, to escape or subvert innate immune responses 
[23]. Previous research has indicated that adenosine synthase 
A (AdsA), an S. aureus cell wall–anchored enzyme, acts as an 
immune evasion factor [22]. When both wild-type and adsA-de-
ficient S. aureus are mixed with fresh mouse or human blood, they 
are phagocytized by polymorphonuclear leukocytes (PMNs), 
particularly phagocytic neutrophils; however, wild-type S. aureus 
survives within PMNs but adsA mutants do not. Furthermore, 
adsA mutant S. aureus were cleared more easily from the BALB/c 
mice bloodstream than wild-type strain, correlating with the 
reduced ability to grow during infection and/or seed abscesses 
[22]. S. aureus generates adenosine by converting from ade-
nosine monophosphates (AMP) or adenosine di-phosphates 
(ADP) after infecting humans or mammals. In mammals, it is 
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a 2-step process to catalyze adenosine triphosphate to adenos-
ine. First, ectonucleoside triphosphate diphosphohydrolases 
(ecto-NTDPases) hydrolyze ATP or ADP to produce AMP. 
AdsA contains two 5ʹ-nucleotidase signature regions, which 
then catalyses the conversion of AMP to adenosine [24].
Bacterial invasion of human or animal tissues activates granu-
locytes to release DNA, thereby fixing pathogens for subsequent 
clearance by macrophage phagocytosis. These networks are called 
neutrophil extracellular traps (NETs), which also act a first line of 
defense against foreign microbes. Recently, Thammavongsa et al 
showed that S. aureus could degrade NET function and induce 
immune cell death [25]. When S.  aureus infects host tissues, 
the bacteria express 2 enzymes, nuclease and AdsA. Nuclease 
can degrade NET DNA into deoxyadenylate (dAMP), which is 
subsequently converted to produce 2’-deoxyadenosine (dAdo) 
by AdsA. dAdo can sufficient activate caspase-3 pathway to pro-
mote apoptosis of macrophages. Therefore, S. aureus can confine 
macrophages from crossing the immune cell cuff into the abscess 
communities. This is the mechanism preventing phagocytosis, 
thereby establishes persistent S. aureus infections [25].
In this study, we tested whether active or passive immuniza-
tion directed at AdsA could alleviate disease severity in 3 infec-
tion BALB/c models.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
Escherichia coli strain BL21 (DE3) was used for protein expres-
sion. The S. aureus Newman [26] and USA300 strains [27] are a 
gift from Dr Richard Yi-Tsun Kao (Department of Microbiology, 
University of Hong Kong). S. aureus strains were grown at 37°C 
in BHI broth or agar. For preparation of bacterial challenge inoc-
ula for infection studies in animals, S. aureus USA300 strains 
were grown 12 hours at 37°C in brain-heart infusion (BHI). The 
next day, inoculation of 50 μL preculture USA300 strains into 5 
mL BHI to subculture at 37°C for 2 hours until mid-exponen-
tial phase is reached (optical density at 600 nm). The bacteria 
were harvested using endotoxin-free phosphate-buffered saline 
(PBS), washed twice, and resuspended with the desired amount 
of colony-forming units (CFU) depending on the model.
Active Immunization
Six-week-old female BALB/c mice (n  =  10 per group) were 
immunized with 25 μg of rAdsA (endotoxin [lipopolysaccha-
ride] was <10 EU/mg, host cell protein was <2  ng/mg, and 
DNA was <0.2 ng/mg) proteins by intramuscular injection. The 
recombinant proteins were formulated at a ratio of 9:1 with alu-
minium hydroxide gel (AHG; Alhydrogel) (100 μL of 2% AHG 
per 900 μL of antigen). These treatments were administered to 
mice on days 0, 14, and 28. Blood samples were drawn from the 
tail vein on days 0, 21, and 35.
Furthermore, to produce polyclonal antibodies, New Zealand 
rabbits (n = 3) were immunized by intradermal injection with 
rAdsA (250 μg of purified protein) adsorbed to AHG (2 mg/mL) 
on days 0, 21, and 42. The rAdsA antibody titer was detected 
by enzyme-linked immunosorbent assay (ELISA) as described 
elsewhere.
Passive Immunization
Rabbit immune sera (200  μL) were injected into the tail vein 
of 8-week-old BALB/C mice 24 hours prior to challenge with 
S. aureus infection according to the skin infection or peritonitis 
models. Control mice were injected with the same volume of 
sera from rabbits that had been immunized with PBS and alu-
minum hydroxide.
Murine Skin Infection Model
Experiments using the mouse skin infection model were per-
formed as previously described [28]. Female BALB/c mice were 
anesthetized with isoflurane ketamine (100  mg/kg) and xyla-
zine (5  mg/kg) and inoculated by subcutaneous injection in 
the right shaved flank with 1 × 107 CFU S. aureus USA300 or 
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Figure 1. Adenosine synthase A (AdsA)–specific antibody responses in immu-
nized mice or rabbit. The lower limit of detection (1:10) is shown as dotted lines. The 
experiment was repeated at least twice. A, AdsA-specific immunoglobulin G (IgG) 
antibody responses in mouse sera collected at 7 days after the third vaccination. 
B, AdsA-specific IgG1 and IgG2a antibody responses. C, AdsA -specific antibody 
responses in rabbit sera obtained 7 days after the third immunization. ***P < .001. 
Abbreviations: Ab, antibody; AdsA, adenosine synthase A; AHA, xxx; AHG, alumi-
num hydroxide gel; IgG, immunoglobulin G; PBS, phosphate-buffered saline.
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Newman strain in 50 μL PBS. Mass and abscess formation (size 
and dermonecrosis) were monitored at 24 hours intervals over 
a course of 2 weeks. The size of an abscess and associated over-
lying dermonecrotic lesion was determined using a standard 
formula for area [A = (π/2) × l × w].
Peritonitis Infection Model
We used a previously described mouse peritonitis model 
[28]. Active (10  days after second immunization) or passive 
immunized BALB/C mice were challenged by intraperitoneal 
injection of S. aureus. Mice were infected with 1 × 108 CFU of 
S. aureus (specific inoculum varied depending on the challenge 
strain) and monitored daily for 14 days.
Blood Infection Model
Active (10 days after second immunization) or passive immu-
nized BALB/C mice were challenged by intravenous injection 
of S. aureus [17, 28]. Mice were infected with 5 × 107 CFU of 
S. aureus and monitored daily for 14 days.
S. aureus Infection In Vitro
RAW264.7 cells were seeded on 24-well culture plates at 1 × 106 
cell/well in RPMI Medium 1640 supplemented with 10% (v/v) 
fetal bovine serum. Cells were treated with 20 μL AdsA-specific 
rabbit antisera and infected simultaneously with S.  aureus at 
multiplicity of infection 10. After incubation for 60 and 120 
minutes, the extracellular and intracellular bacteria were enu-
merated by serial dilution and spread on BHI agar plates.
Bacterial Survival in Blood
Whole blood was collected by cardiac puncture of BALB/c mice, 
and 5 μg/mL of lepirudin anticoagulant was immediately added. 
One hundred microliters of 106 CFU/mL of S.  aureus strain 
USA300 was mixed with 900 μL of BALB/C mouse blood. The 
tubes were incubated at 37°C with slow rotation for the time 
points indicated in the figures, at which time aliquots were incu-
bated on ice for 30 minutes in a final concentration of 0.5% sapo-
nin/PBS to lyse eukaryotic cells. Dilutions of staphylococci were 
plated on BHI agar plates for enumeration of surviving CFUs.
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Figure 2. Active immunization with adenosine synthase A (AdsA) decreases the size of abscesses caused by USA300 or Newman strains of S. aureus. Mice were injected 
intramuscularly with aluminum hydroxide gel (AHG) plus phosphate-buffered saline (PBS). A, Abscess formation was monitored once per day after subcutaneous infection 
with 1 × 107 of the indicated bacteria 49 days after primary immunization. Results are the mean value ± standard error of the mean; n = 12 mice per group. *P ＜ .05 vs wild-
type USA300 or Newman strains using a 2-way analysis of variance and Bonferroni posttest. B, Percentage of mice per group that had dermonecrosis on each day. P ＜ .001 
for mock immunized mice after infection with either Newman or USA300 strains over the 14-day time course. C, Representative mouse skin lesions on day 4. Black arrows 
indicate dermonecrosis; white arrows indicate abscess formation without dermonecrosis.
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Flow Cytometry
Flow cytometry was used to detect the apoptotic and necrotic 
rate. RAW264.7 (1 × 106) cells were treated with AdsA-specific 
rabbit antisera or normal rabbit serum and simultaneously 
infected with S. aureus strain USA300 (10 MOI). After the 
RAW264.7 cells had been exposed to S. aureus strain USA300 
for 3 hours in vitro, Then the cells were harvested and incubated 
with Annexin V conjugated to green-fluorescent FITC dye and 
propidium iodide (PI), and then analyzed at 525 nm for FITC 
and at 630 nm for PI using BD Accuri C6 flow cytometer (BD).
Statistical Analysis
Log-rank (Mantel-Cox) analysis was used to analyze the statisti-
cal significance of the data from the lethal challenge experiment. 
Analyses were performed using GraphPad Prism 5 (GraphPad 
Software, United States) and a P value <.05 was determined to 
be statistically significant.
Research Ethics
SPF BALB/c mice and New Zealand rabbits were supplied by 
the Laboratory Animal Unit of the University of Hong Kong. 
All animal experiments were approved by the Committee on the 
Use of Live Animal in Teaching and Research of the University 
of Hong Kong (CULATR 2596-11).
RESULTS
Antibody Quantification
To investigate the antibody titers of AdsA-specific antibodies 
in the sera of immunized mice, the levels of immunoglobulin 
G (IgG), IgG1, and IgG2a antibodies were detected by ELISA 
7 days after the third immunization. The data showed that immu-
nization with the AdsA recombinant protein induced high lev-
els of anti-AdsA IgG (>1:105; day 42) (Figure 1A). Furthermore, 
immunization with AdsA in the presence of AHG elicited both 
T helper 1– and T helper 2–associated AdsA-specific IgG2a and 
IgG1 antibody responses (Figure 1B). IgG, IgG1, and IgG2a spe-
cific for AdsA were not detected in the serum of mice mock 
immunized with PBS plus AHG. In addition, ELISA of rabbit 
serum samples was obtained after the second boost (day 42). 
As shown in Figure 1C, immunization with AdsA induced high 
levels of anti-AdsA IgG (>1:107) in a rabbit model.
Immunization With AdsA Induces Consistent Protective Immunity Against 
2 Staphylococcal Strains in 3 Mouse Models
To assess the protective efficacy of AdsA against different S. 
aureus disease outcomes, we used a skin infection model. In the 
skin infection model, mice were inoculated by subcutaneous 
injection in the shaved right flank with S. aureus Newman or 
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Figure 3. Survival curve of vaccinated BALB/c mice challenged with S. aureus. Mice were challenged intravenously (A) or intraperitoneally (B) with S. aureus Newman and 
USA300 strains. The results of 2 independent experiments (mice, n = 10) are shown. The P value represents the likelihood of a significant difference between all groups by 
pairwise log-rank analysis. *P < .05; **P < .01. Abbreviations: AdsA, adenosine synthase A; AHG, aluminum hydroxide gel; i.p., intraperitoneal; i.v., intravenous.
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USA300 strain. In both the vaccinated and control sets of ani-
mals, abscess mass and dermonecrotic area were monitored at 
24-hour intervals for 14 days. S. aureus abscess size was reduced 
significantly in mice vaccinated with AdsA (Figure 2A). In addi-
tion, there was little or no dermonecrosis in infected mice that 
had been vaccinated (Figure 2B and 2C), which demonstrates 
that active immunization with AdsA alleviates the severity of S. 
aureus skin infections. The protective efficacy of AdsA was fur-
ther investigated with 2 additional models. First, after immuni-
zation, mice were challenged intravenously with a lethal dose 
of either USA300 or Newman strain, and we followed mouse 
survival over a period of 14 days. As shown in Figure 3A, the 14 
days protection elicited by AdsA ranged from 37.5% (USA300) 
to 50% (Newman) and was always significantly superior to that 
observed in mock. Second, we tested the protective efficacy of 
AdsA in the peritonitis model, challenging mice with a lethal 
dose of either USA300 or Newman strain, and we also moni-
tored daily for 14 days. In the model, compared with the control 
mice treated with PBS + AHG, mice vaccinated with combined 
AdsA + AHG had significant protective immunity to Newman 
(62.5%; P = .011, log-rank Mantel-Cox test) and USA300 (50%; 
P = .017, log-rank Mantel-Cox test) S. aureus strains (Figure 
3B).
Passive Immunization With AdsA-Specific Antisera Reduces 
Staphylococcal Infection in Mouse Models
Inasmuch as AdsA contributed to disease severity in the mouse 
infection model, we further investigated whether passive immu-
nization with AdsA-specific antibody would reduce the severity 
of S. aureus disease in infected mice. To this aim, 2 rabbits were 
immunized with AdsA, and subsequently the rabbit serum was 
used in passive protection experiments. Specifically, 200 μL of 
serum was administered intraperitoneally to mice, and 2 hours 
later animals were challenged with S. aureus of either USA300 
or Newman strain accordingly in the skin, blood, and peritoneal 
models. Skin lesions of mice infected with Newman or USA300 
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Figure 4. Evaluation of the therapeutic effects of anti–adenosine synthase A (AdsA) rabbit serum in the BALB/c mouse model. Mice were challenged by intravenous injec-
tion of S. aureus. After 2 hours, the experimental groups were treated with anti- AdsA rabbit serum, whereas control mice were injected with normal rabbit serum. The P value 
represents the likelihood of a significant difference between all groups by pairwise log-rank analysis. A, Abscess formation was monitored once per day after subcutaneous 
infection with 1 × 107 of the indicated bacteria 2 hours after passive immunization. Results are the mean value ± standard error of the mean; n = 12 mice per group. *P ＜ .05 
vs wild-type USA300 or Newman strains using a 2-way analysis of variance and Bonferroni posttest. B, Percentage of mice per group that had dermonecrosis on each day. 
P ＜ .001 for mock-immunized mice after infection with either Newman or USA300 strains over the 14-day time course. C, Representative mouse skin lesions on day 4. Black 
arrows indicate dermonecrosis; white arrows indicate abscess formation without dermonecrosis.
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strains were significantly smaller after passive immunization 
with AdsA-specific rabbit antisera, compared with lesions of 
mice that received preimmune serum samples (Figure 4A). The 
percentage of dermonecrosis in mice that received the AdsA-
specific rabbit antisera was significantly lower than in control 
animals (Figure  4B and 4C). Likewise, survival of passively 
immunized mice to the intravenous (Newman: 60% vs 20%; 
USA300: 30% vs 0) or intraperitoneal (Newman: 50% vs 10%; 
USA300: 30% vs 0) S. aureus challenge was significantly greater 
than that of the control group (Figure 5).
AdsA-Specific Antisera Promotes Killing S. aureus by Immune Cell
Specially, we examined the protective effect of anti-AdsA anti-
bodies in vitro. A  murine macrophage cell line, RAW264.7, 
was treated with AdsA-specific rabbit antisera and simulta-
neously infected with S. aureus strain USA300. Extracellular 
and intracellular bacterial number was enumerated at 2 time 
points. As shown in Figure  6A and 6B, the anti-AdsA anti-
body is able to modulate bacterial number in culture medium 
and invasion into RAW264.7 cells. The results demonstrated 
that the anti-AdsA antibodies reduce extracellular and intra-
cellular number of S.  aureus in murine macrophages. To 
further identify whether the AdsA-specific antisera function-
ally affects bacterial–host cell interactions, we detected the 
ability of S. aureus strain USA300 to survive in whole blood 
collected from AdsA- or Mock (PBS  +  AHG)–immunized 
BALB/c mice by recording bacterial load at timed intervals 
via the formation of colonies on BHI agar plate. As expected, 
the blood from Mock-immunized BALB/c mice, which lack 
AdsA-specific antibodies, was unable to kill the bacteria 
(Figure  6B). In the contrast to the blood from Mock mice, 
immunized mice acquiring the AdsA-specific antibodies 
were blocked in staphylococcal escape from phagocytic kill-
ing (P  <  .05; Figure  6B). To discern whether AdsA-specific 
antibodies enhance bacterial clearance in the bloodstream, 
BALB/c mice were infected by intravenous inoculation with 
5 × 107 CFU and peripheral blood was enumerated with CFU 
at 3 and 5 hours postinfection. As shown in Figure 6C, signifi-
cantly lower CFUs of AdsA-immunized mice were observed 
at 3 hours (P = .0412) and 5 hours (P = .0055) postinfection 
as compared with the Mock-immunized group. Altogether, 
these data suggest that the anti-AdsA antibody can reduce 
virulence of staphylococci, thereby decreasing the bacteria 
survival in blood.
Moreover, to examine whether inhibited AdsA activity 
reduces cell damage correlated with levels of apoptosis and 
necrosis, RAW264.7 cells were treated with AdsA-specific 
rabbit antisera and simultaneously infected with S.  aureus 
strain USA300. After the RAW264.7 cells had been exposed 
to S.  aureus strain USA300 for 3 hours in vitro, we analyzed 
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cells for apoptosis, namely externalization of phospholipids (an 
early event detected by Annexin V) and necrosis (permeability 
to PI). As shown in Figure 6D, the percentage of normal rabbit 
serum–treated cells (healthy cells: ∼66%) was significantly more 
cell death than anti-AdsA–treated cells (healthy cells: ∼75%); 
Additionally, the anti-AdsA–treated group had low proportion 
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of Annexin V and PI dual-positive cells (late apoptotic or sec-
ondary necrotic,∼5.5%) and PI-positive cells (necrotic, ∼3%) 
(Figure 6D and 6E). Interestingly, the anti-AdsA–treated group 
had the highest proportion of Annexin V–positive cells (early 
apoptotic: ∼16%) compared with normal rabbit serum–treated 
cells (early apoptotic: ∼8%) (Figure 6D and 6E). Overall, these 
results indicate that the anti-AdsA antibody may delay apopto-
sis and protect necrosis during S. aureus infection.
DISCUSSION
S. aureus is a leading cause of skin and soft tissue infections, 
sepsis, bacteremia, osteomyelitis, meningitis, pneumonia, 
and endocarditis [23]. A large proportion of cases and deaths 
have been attributed to the ability of S. aureus to escape innate 
responses. In mammals, adenosine plays a key role in regulating 
innate and acquired immune responses [29]. Strong or super-
abundant host immune responses exacerbate the tissue damage 
caused by invading pathogens [29] such as S. aureus infection. 
Successful immune clearance of pathogens involves the bal-
ancing of proinflammatory and anti-inflammatory cytokines. 
The cytokines interleukin (IL) 13, IL-10, IL-4, and transform-
ing growth factor–β function to restrict strong inflammation, 
whereas adenosine has the ability to totally suppress the immune 
response [30]. Phagocytes express 4 adenosine transmembrane 
receptors according to their activation state: A1AR, A2aAR, 
A2bAR, and A3AR [31]. Adenosine, mediated by A2aAR in 
monocytes [32] and dendritic cells [33], inhibits proinflamma-
tory cytokine production, particularly IL-12 and tumor necro-
sis factor–α, while increasing the level of the anti-inflammatory 
cytokine IL-10. Extracellular adenosine is necessary for the 
regulation of inflammation, but excess production of adenosine 
is also harmful as in S. aureus infections [22]. S. aureus AdsA 
produces excessive adenosine, which disrupts the balance of 
the proinflammatory and anti-inflammatory response. S. aur-
eus survival in PMNs depends on adenosine receptor–mediated 
signaling. In addition, adenosine may also suppress adaptive 
immune responses by interfering with the antigen-presenting 
cells to present S. aureus antigens [34].
Bacterial invasion of host tissues triggers neutrophil extracel-
lular traps (NETs), thereby immobilizing pathogens or subse-
quent clearance. However, AdsA also has an ability to modulate 
immune responses following the degradation of NETs by pro-
moting macrophage apoptosis [25]. Although a great number 
of infiltrated neutrophils migrate to the infection sites, host 
immunity may not be able to eliminate S. aureus from abscess 
lesions and eventually succumb to persistent infection. The 
strong impact that AdsA has on the development of S. aureus 
persistent infection disease identifies the protein as a prom-
ising target for drug development. Two routes using AdsA as 
immunotherapy targets can be envisaged. First, AdsA could be 
used as an antigen in active vaccination approaches. Second, 
AdsA could be targeted by antibodies. To test this hypothesis, 
we decided to use 3 mouse infection models to test AdsA as a 
candidate antigen for S. aureus vaccine. We showed that mice 
immunized with AdsA plus AHG adjuvant was protected 
against S. aureus skin and lethal infection. Although AdsA 
could decrease the severity of S. aureus diseases, it is not clear 
whether anti-AdsA antibody-biased immune responses con-
ferred this protection. To dissect the possible mechanisms of 
protection induced by AdsA, we focused our attention on the 
analysis of polyclonal antibodies. To this aim, rabbits were 
immunized with AdsA, and subsequently the rabbit serum was 
used in passive protection experiments. Our results indicated 
that anti-AdsA specific antibodies can decrease the severity of 
S. aureus infection in different mouse models. To reveal how the 
AdsA-specific antibody functionally affects bacterial–host cell 
interactions, RAW264.7 cells were treated with AdsA-specific 
rabbit antisera and simultaneously infected with S. aureus strain 
USA300. The results demonstrated that the Anti-AdsA anti-
bodies can reduce extracellular and intracellular numbers of S. 
aureus in murine macrophages. AdsA is required for staphylo-
coccal survival in blood [22]. Therefore, we also examined the 
ability of anti-AdsA–specific antibodies to block staphylococcal 
escape from phagocytic killing. As expected, the AdsA-specific 
antisera not only rescues phagocytic killing of immune cells, 
but also enhances the bacterial clearance in the bloodstream. S. 
aureus can cause liquefaction necrosis, AMP levels are expected 
to increase as a consequence of staphylococcal toxins (eg, leu-
kocidins, α-hemolysin) that form pores in membranes and pre-
cipitate cellular lysis [35]. Furthermore, production of dAdo by 
AdsA is sufficient to induce apoptosis of macrophages via the 
activation of caspase-3 [25]. Our results suggest that the anti-
AdsA antibody may protect necrosis and delay apoptosis during 
S. aureus infection.
The active and passive immunization data presented here 
suggest that AdsA is a potential antigen for vaccines or thera-
peutics designed to alleviate the severity of S. aureus infections. 
Inasmuch as AdsA is present in all strains and highly conserved, 
an immunotherapeutic approach directed at AdsA would be 
relatively broad in scope.
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